Diabetes, insulin and new therapeutic strategies for Parkinson's disease: Focus on glucagon-like peptide-1 receptor agonists
| Autor: | Ana I. Rodriguez-Perez, Carmen M. Labandeira, David Arias Ron, Arturo Fraga-Bau, Antonio Koukoulis, Ana Muñoz, Jesus Romero-Lopez, Gema Alonso-Losada |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Parkinson's disease medicine.medical_treatment Disease Bioinformatics Neuroprotection Glucagon-Like Peptide-1 Receptor 03 medical and health sciences 0302 clinical medicine Diabetes mellitus medicine Diabetes Mellitus Humans Hypoglycemic Agents Insulin Neuroinflammation biology Endocrine and Autonomic Systems business.industry Neurodegeneration Parkinson Disease medicine.disease Insulin receptor 030104 developmental biology Diabetes Mellitus Type 2 biology.protein business 030217 neurology & neurosurgery |
| Zdroj: | Frontiers in neuroendocrinology. 62 |
| ISSN: | 1095-6808 |
| Popis: | Parkinson's disease and diabetes mellitus are two chronic disorders associated with aging that are becoming increasingly prevalent worldwide. Parkinson is a multifactorial progressive condition with no available disease modifying treatments at the moment. Over the last few years there is growing interest in the relationship between diabetes (and impaired insulin signaling) and neurodegenerative diseases, as well as the possible benefit of antidiabetic treatments as neuroprotectors, even in non-diabetic patients. Insulin regulates essential functions in the brain such as neuronal survival, autophagy of toxic proteins, synaptic plasticity, neurogenesis, oxidative stress and neuroinflammation. We review the existing epidemiological, experimental and clinical evidence that supports the interplay between insulin and neurodegeneration in Parkinson's disease, as well as the role of antidiabetic treatments in this disease. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect